Amarin Corp Plc (AMRN)

[north40000]

The idea expressed by you, Marzan, are worth thinking about; a “conditional” approval of a broad label FDA agrees with; a still broader label possible after AdCom views are expressed.

We have yet to consider the effect of agreed upon views of AHA and ACC re SOC that could be published any time by Dr. Bhatt as editor of at least one ACC journal. Off-label scrips should then increase substantially, much like effect of ADA recommendations late March.